Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464395 | 0.78 | HSD11B1 (0.48) | HSD11B1CA2CA1CA12CA3 | |
| SCHEMBL16232172 | 0.74 | HSD11B1 (0.46) | HSD11B1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL6550967 | 0.73 | CES1 (0.45) | HSD11B1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL28797596 | 0.73 | MAPT (0.47) | HSD11B1CA2CA1CA12CA3 | |
| SCHEMBL10652867 | 0.73 | TSHR (0.48) | HSD11B1CA2CA1CA12CA3 | |
| SCHEMBL28442855 | 0.73 | CA1 (0.48) | HSD11B1CA2CA1CA12CA3 | |
| SCHEMBL384939 | 0.72 | HTR6 (0.50) | HSD11B1CA2CA1CA12CA3 | |
| SCHEMBL6544675 | 0.72 | HTR6 (0.50) | HSD11B1CA2CA1CA12CA3 | |
| SCHEMBL780280 | 0.72 | ALDH1A1 (0.60) | HSD11B1CA2CA1CA12CA3 | |
| SCHEMBL16842663 | 0.72 | HSD11B1 (0.51) | HSD11B1TSHRSMN1; SMN2HTR6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032518-A1 | Compounds and methods of use | AMGEN INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20060241151-A1 | Pyrid-2-one derivatives and methods of use | AMGEN, INC. (US) | 2006-10-26 | — | — | US | disclosed |
| EP-1575947-A1 | 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | Amgen Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6822097-B1 | THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS | AMGEN, INC. | 2004-11-23 | — | — | US | disclosed |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | SYNGENTA CROP PROTECTION AG (CH) | 2004-07-29 | — | — | US | disclosed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032518-A1 | Compounds and methods of use | BAX, BAD, CASP3 | HSD11B1 750/4885CA2 1951/4885CA1 1217/4885 |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | HSD11B1 2038/4885CA2 3828/4885CA1 4152/4885 |
| US-20060241151-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | HSD11B1 2034/4885CA2 3733/4885CA1 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.